AndroGel Variable Absorption That Doesn't Resolve: Causes, Management, and When to Switch

Why AndroGel Absorption Varies So Much Between Patients

Testosterone gel relies on passive diffusion through the stratum corneum, the outermost skin layer that functions as a barrier against the external environment. The thickness and lipid composition of this layer differ significantly from person to person, and even from one body site to another on the same individual. A pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that transdermal testosterone delivery shows a coefficient of variation (CV) of 20-40% across subjects, far higher than the CV seen with intramuscular injections [1].

Several physiological factors drive this inconsistency. Subcutaneous fat thickness at the application site affects how much testosterone partitions into adipose tissue before reaching capillaries. Men with higher body fat percentages at the shoulder or abdomen may absorb less active drug into systemic circulation. Skin hydration also matters. Dry, keratinized skin slows diffusion, while freshly showered or excessively moist skin can alter the gel vehicle's evaporation rate and change how much testosterone penetrates the epidermis.

The gel formulation itself plays a role. AndroGel uses a hydroalcoholic vehicle that must evaporate within 5-10 minutes to deposit testosterone on the skin surface. If the alcohol evaporates too quickly (in hot, dry environments) or too slowly (in humid conditions), the drug deposition profile shifts. The FDA prescribing information for AndroGel 1.62% warns that application site, skin condition, and ambient temperature all affect absorption [2].

The Skin Barrier Problem: When Biology Works Against You

Some men have constitutionally thicker stratum corneum or different ceramide-to-cholesterol ratios in their skin lipids, and these features are not modifiable through behavioral changes. A 2004 study in Skin Pharmacology and Physiology found that epidermal barrier function varies by up to 3-fold across healthy adult males of similar age and ethnicity [3]. This biological variability means that no matter how perfectly a patient applies the gel, his skin may simply not allow consistent passage of testosterone molecules into the dermal capillary bed.

Age compounds the problem. The stratum corneum thickens with age while dermal vascularity decreases. Men over 60, who represent a large segment of the TRT population, often have reduced percutaneous absorption compared to younger men. A pharmacokinetic analysis in Clinical Pharmacokinetics confirmed that older skin delivers less drug per unit area per hour than younger skin for multiple transdermal formulations [4].

Scarring, eczema, psoriasis, and other dermatologic conditions at or near the application site can also disrupt the barrier in unpredictable ways. The result is serum testosterone levels that bounce between subtherapeutic and mid-range on consecutive lab draws, even when the patient reports identical application technique each day.

Behavioral Factors That Make Variable Absorption Persist

Application technique errors account for a large share of persistent absorption problems, and many patients never receive proper instruction. The gel must be applied to clean, dry, intact skin. It should not be rubbed in aggressively. The site must remain uncovered and unwashed for at least 2 hours (AndroGel 1%) or 5 hours (AndroGel 1.62%).

Showering within 1-2 hours of application can wash away 30-50% of the applied dose. A crossover study published in the Journal of Sexual Medicine showed that washing the application site just 1 hour after gel application reduced the 24-hour testosterone AUC by approximately 35% compared to leaving the site unwashed for 6 hours [5]. Exercise-induced sweating within the first 2 hours creates a similar washout effect.

Clothing contact transfers testosterone away from the skin and onto fabric. This is the same mechanism behind the FDA black-box warning about secondary transfer to women and children [6]. Tight-fitting shirts applied over the shoulders shortly after gel application can wick drug off the skin surface before absorption is complete.

Sunscreen, moisturizer, and other topical products applied before or after the gel can create a physical or chemical barrier. Mineral sunscreens containing zinc oxide form an occlusive layer. Alcohol-based products may interact with the gel vehicle. The prescribing information explicitly states that patients should not apply other products to the same site until the gel has fully dried [2].

How to Tell If Your Absorption Problem Is Persistent

A single low testosterone level does not confirm a persistent absorption issue. Serum testosterone fluctuates throughout the day, and topical formulations produce a different diurnal pattern than the body's natural rhythm. The Endocrine Society's 2018 clinical practice guideline recommends checking total testosterone 2-4 hours after gel application, which is when levels typically peak [7].

Persistent variable absorption shows a specific pattern on labs: the CV across 3 or more trough or post-application levels (drawn under identical conditions) exceeds 30%. If one draw shows 450 ng/dL, the next shows 280 ng/dL, and a third shows 520 ng/dL despite no changes in dose, application site, timing, or technique, the absorption is genuinely erratic.

Symptom cycling is the clinical correlate. Men with persistent absorption variability often report days of feeling well-optimized (good energy, stable mood, adequate libido) alternating with days of fatigue, brain fog, and irritability. This symptom pattern mirrors the serum level oscillation.

Your clinician should rule out compliance issues first. A review in Therapeutic Advances in Urology found that adherence to daily topical testosterone regimens drops below 70% by 12 months [8]. Missed doses or inconsistent timing can mimic absorption variability. An honest conversation about real-world application habits is the first diagnostic step.

Clinical Strategies for Managing Persistent Variable Absorption

When behavioral optimization fails to stabilize levels after 60-90 days, several dose-adjustment and formulation strategies exist before abandoning topical therapy entirely.

Dose titration with serial monitoring. Increasing the gel dose by one pump or packet and rechecking levels at 2-4 hours post-application after 14 days can overcome a partially resistant skin barrier. The AndroGel 1.62% label allows titration from 40.5 mg to 81 mg daily based on serum levels [2]. Dose increases should be supervised because supraphysiologic absorption on "good absorption days" can push levels above 1 to 000 ng/dL and increase erythrocytosis risk.

Application site rotation. Switching from shoulders to abdomen (or vice versa, depending on the formulation approved for each site) can sometimes find a site with better absorption characteristics. A pharmacokinetic comparison in Drug Design, Development and Therapy showed that abdominal application produced 20-30% higher bioavailability than shoulder application for 1.62% testosterone gel in some subjects [9]. Skin thickness is generally thinner on the abdomen than on the deltoid region.

Formulation switch within topicals. Testosterone solutions (such as Axiron, applied to the axillae) use a different vehicle and application site. The axillary skin is thinner and more vascular, which may produce more consistent absorption in men who struggle with gel formulations. A head-to-head pharmacokinetic study demonstrated that axillary testosterone solution achieved a lower intra-subject CV than shoulder-applied gel in a subset of participants [10].

Compounded testosterone cream. Some clinics prescribe compounded testosterone in a cream base (typically 100-200 mg/mL) applied to the scrotum, where skin is thin and highly vascular. A 2019 study in the International Journal of Impotence Research reported that scrotal application of compounded testosterone cream produced peak levels 5-8 times higher than conventional-site application, with a different DHT-to-testosterone ratio [11]. This approach is off-label for commercial gels and requires compounding pharmacy access.

When to Abandon Topical Testosterone Entirely

If three or more lab draws over a 90-day period (with confirmed proper technique, consistent timing, and no interfering products) show a total testosterone CV exceeding 35%, topical therapy is unlikely to provide stable hormone replacement for that patient.

The American Urological Association's 2018 guideline on testosterone deficiency lists intramuscular testosterone cypionate and subcutaneous testosterone pellets as first-line alternatives for men who cannot achieve stable levels with topical formulations [12]. Injectable testosterone cypionate (100-200 mg every 1-2 weeks, or 50-80 mg twice weekly for more stable levels) bypasses the skin barrier completely. It produces predictable pharmacokinetics with a serum level CV typically below 15% on a stable dose.

Subcutaneous testosterone pellets (such as Testopel, 150-450 mg implanted every 3-4 months) offer the most consistent serum levels of any TRT formulation. A retrospective cohort study in The Journal of Urology found that pellet-treated men had the highest satisfaction scores and lowest rate of level-related complaints compared to gel and injection users [13].

Nasal testosterone (Natesto, 11 mg per nostril two or three times daily) is another non-skin option, though its short half-life requires multiple daily doses and produces a pulsatile level pattern that some men find suboptimal.

Monitoring After Switching Away From Topical Therapy

After transitioning to an injectable or pellet formulation, confirm that the absorption problem has resolved by checking total testosterone, free testosterone, hematocrit, and PSA at 6 weeks, 3 months, and then every 6-12 months per the Endocrine Society's monitoring protocol [7].

Hematocrit deserves particular attention during the transition. Men with previously variable absorption may have been intermittently exposed to supraphysiologic levels on high-absorption days, which can stimulate erythropoiesis. Switching to a formulation with consistently higher bioavailability might push hematocrit above the 54% threshold that triggers dose reduction or therapeutic phlebotomy. A 2014 meta-analysis in JAMA Internal Medicine identified polycythemia as the most common adverse effect of testosterone therapy across all formulations [14].

Estradiol levels should also be checked 6-8 weeks after switching. Higher and more consistent testosterone delivery increases aromatase-mediated conversion to estradiol. Men who were symptomatically fine on variable topical levels may develop nipple tenderness or fluid retention when steady-state injectable levels run 200-300 ng/dL higher than their previous topical average.

The Role of FAERS Data in Understanding Persistent Absorption Issues

The FDA Adverse Event Reporting System (FAERS) captures post-marketing safety signals for all approved drugs [15]. Testosterone topical products generate a consistent volume of reports related to "drug ineffective," "drug level increased," and "drug level decreased," which are proxy terms for absorption variability. These reports do not establish causation, but the recurring pattern across thousands of reports confirms that variable absorption is not a rare idiosyncrasy.

FAERS data also reveal that absorption complaints cluster among men over 55, men with BMI above 30, and men using concomitant dermatologic products. These demographic patterns align with the pharmacokinetic predictors discussed above and reinforce the idea that certain patient profiles are biologically predisposed to poor or inconsistent transdermal drug delivery.

What the Research Still Doesn't Answer

No randomized controlled trial has directly compared "absorption optimizers" (exfoliation protocols, chemical penetration enhancers, occlusive dressings) with standard application in men with documented variable absorption. The evidence for skin preparation techniques is limited to small crossover studies and expert opinion.

Genetic variation in skin barrier genes like FLG (filaggrin) is well-characterized in dermatology but has not been studied specifically in the context of transdermal testosterone pharmacokinetics. A genome-wide association study framework for filaggrin mutations and atopic dermatitis exists [16], but no one has mapped FLG variants to testosterone gel absorption rates. This represents a significant research gap.

Until precision-medicine tools can predict which men will absorb topical testosterone reliably, the clinical approach remains empirical: try the gel, monitor levels, optimize technique, and switch formulations if levels stay erratic after 90 days of best-practice application.